Advertisement
The Zenith Award, AARC's top industry recognition award, is presented tocompanies selected by the 44,000 members of AARC based upon the quality ofequipment and/or supplies, accessibility and helpfulness of sales personnel,responsiveness, service record, truth in advertising and support of therespiratory care profession.
Advertisement
"We are honored that the AARC membership has chosen to recognize us forthe second year in a row with this prestigious award," said Ikaria's ExecutiveChairman David Shaw. "The Zenith Award reflects Ikaria's continued leadershipin the respiratory care market, and its commitment to providing respiratorytherapists with the highest quality service, continuing education programs andcritical care technology. It is a source of great satisfaction for everyone atIkaria to be in a position to serve the needs of the critically ill."
About INOmax
INOmax, in conjunction with ventilatory support and other appropriateagents, is used for the treatment of term and near-term ( > 34 weeks) neonateswith hypoxic respiratory failure associated with clinical or echocardiographicevidence of pulmonary hypertension.
INOmax is designed to help critically ill newborns breathe moreeffectively by dilating the blood vessels of the lungs, which improves oxygenuptake and oxygen supply to the tissues of the body. INOmax therapy has beenshown to reduce the need for a highly invasive surgical procedure known asextracorporeal membrane oxygenation, or ECMO. During ECMO, an infant's bloodis mechanically oxygenated by connecting the baby to a heart-lung machine.
INOmax should not be used in the treatment of neonates known to bedependent on right-to-left shunting of blood. Abrupt discontinuation of INOmaxmay lead to a worsening condition. Methemoglobinemia is a dose-dependent sideeffect of inhaled nitric oxide therapy. Nitrogen dioxide (NO2) forms rapidlyin gas mixtures containing nitric oxide and oxygen and thus may cause airwayinflammation and damage. Methemoglobin, NO2, and the fraction of inspiredoxygen (FiO2) should be monitored during nitric oxide administration.
For more information on INOmax, including important safety and completeprescribing information, please visit INOmax.com.
About Ikaria Holdings, Inc.
Ikaria Holdings, Inc. is a fully integrated biotherapeutics companyfocused on the development and commercialization of innovative in-hospitalpharmaceutical products and drug/device combinations for the critically ill.The company's product, INOmax(R) (nitric oxide) for inhalation, is anFDA-approved drug for the treatment of hypoxic respiratory failure in term andnear-term newborns. The drug also is approved by regulatory authorities andused in Canada, Europe, Australia and Latin America. In addition to marketingand selling its INOmax product, Ikaria is engaged in both Phase II trials withCovox(R) (carbon monoxide) for inhalation and Phase I trials with hydrogensulfide (H2S) for various indications. Ikaria has a staff of over 300 peopleand is headquartered in Clinton, NJ, with research facilities in Seattle, WAand Madison, WI and manufacturing in Port Allen, LA. For more information onIkaria, please visit www.ikaria.com.Liz Larkin Ikaria 908-238-6645 [email protected] Jason Rando/Catherine Bright The Ruth Group 646-536-7025/7013 [email protected] [email protected]
SOURCE
